Asset Details
Do you wish to reserve the book?
Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer
Do you wish to request the book?
Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer
2018
Overview
ObjectivesRecent studies demonstrate autoantibodies are powerful tools to interrogate molecular events linking cancer and the development of autoimmunity in scleroderma. Investigating cancer risk in these biologically relevant subsets may provide an opportunity to develop personalised cancer screening guidelines. In this study, we examined cancer risk in distinct serologic and phenotypic scleroderma subsets and compared estimates with the general population.MethodsPatients in the Johns Hopkins Scleroderma Center observational cohort were studied. Overall and site-specific cancer incidence was calculated in distinct autoantibody and scleroderma phenotypic subsets, and compared with the Surveillance, Epidemiology and End Results registry, a representative sample of the US population.Results2383 patients with scleroderma contributing 37 686 person-years were studied. 205 patients (8.6%) had a diagnosis of cancer. Within 3 years of scleroderma onset, cancer risk was increased in patients with RNA polymerase III autoantibodies (antipol; standardised incidence ratio (SIR) 2.84, 95% CI 1.89 to 4.10) and those lacking centromere, topoisomerase-1 and pol antibodies (SIR 1.83, 95% CI 1.10 to 2.86). Among antipol-positive patients, cancer-specific risk may vary by scleroderma subtype; those with diffuse scleroderma had an increased breast cancer risk, whereas those with limited scleroderma had high lung cancer risk. In contrast, patients with anticentromere antibodies had a lower risk of cancer during follow-up (SIR 0.59, 95% CI 0.44 to 0.76).ConclusionsAutoantibody specificity and disease subtype are biologically meaningful filters that may inform cancer risk stratification in patients with scleroderma. Future research testing the value of targeted cancer screening strategies in patients with scleroderma is needed.
Publisher
Elsevier Limited
Subject
/ Antibodies, Antinuclear - blood
/ Breast Neoplasms - epidemiology
/ Breast Neoplasms - immunology
/ Female
/ Humans
/ Lung Neoplasms - epidemiology
/ Lupus
/ Male
/ Mutation
/ Patients
/ Scleroderma, Diffuse - complications
/ Scleroderma, Diffuse - epidemiology
/ Scleroderma, Diffuse - immunology
/ Scleroderma, Localized - complications
/ Scleroderma, Localized - epidemiology
/ Scleroderma, Localized - immunology
/ Studies
